Tawbi reported recently early results of relatlimab, a lymphocyte-activation gene 3(LAG-3)-blocking antibody, and nivolumab versus nivolumab alone in untreated advanced melanoma (RELATIVITY-047trial) [74]. The gene discussed is LAG3; the disease is melanoma.